Source: International Congress 2016 – Airway response to infection
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Karin Provost (Orchard Park, United States of America), Karin Provost, Miyuki Smith, Anna Miller-Larsson, Gregory Gudleski, Sanjay Sethi. Differential effects of budesonide and fluticasone propionate on bacterial recognition receptors in COPD macrophages. Eur Respir J 2016; 48: Suppl. 60, 3978

Member's Comments

No comment yet.

Related content which might interest you: Differential effects of budesonide and fluticasone propionate on immune defense genes in human bronchial epithelium Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015 Comparison of budesonide and fluticasone propionate on COPD macrophage phagocytosis and killing of bacteria Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Comparison of fluticasone propionate and budesonide on phagocytosis of common respiratory pathogens in COPD patients Source: Annual Congress 2011 - Immunology and cell biology of asthma and COPD Year: 2011 Budesonide and fluticasone propionate exertdifferential effects on human bronchial epithelial cells exposed to streptococcus pneumoniae and viral mimetic Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 Differential effects of budesonide and fluticasone propionate on expression of lactotransferrin in airway epithelium Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Differential effects of budesonide and fluticasone propionate on bronchial epithelial barrier function Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Long-term effect of salmeterol and fluticasone propionate on β2-integrin mediated adhesion of neutrophils: role of annexin-1 in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 103s Year: 2006 Anti-inflammatory effect of the combination of a long acting beta2-agonist (salmeterol) and a corticosteroid (fluticasone propionate) on human airway epithelial cells following Staphylococcus aureus infection Source: Eur Respir J 2005; 26: Suppl. 49, 98s Year: 2005 Multiple synergistic effects of fluticasone propionate and salmeterol on T-cell activation in bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 250s Year: 2004 Anti-inflammatory effect of the combination of a long acting β2-agonist (salmeterol) and a corticosteroid (fluticasone propionate) on human airway epithelial cells following staphylococcus aureus virulence factors challenge Source: Eur Respir J 2006; 28: Suppl. 50, 104s Year: 2006 Additive blockade of β2-integrin adhesion of eosinophils by salmeterol and fluticasone propionate Source: Eur Respir J 2004; 23: 511-517 Year: 2004 Comparison of fluticasone, roflumilast and tiotropium in a model of influenza-induced acute COPD exacerbation Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Differential effect of fluticasone on Poly(I:C) induced TSLP secretion by bronchial epithelial cells from asthmatic children Source: International Congress 2016 – Mechanisms of disease Year: 2016 The effects of treatment with fluticasone propionate alone and combination with salmeterol on asthma control and airway inflammation Source: Eur Respir J 2003; 22: Suppl. 45, 287s Year: 2003 Effects of a single inhaled budesonide/formoterol dose on glucocorticoid receptor activity in sputum of COPD patients Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 Fluticasone propionate reduces bacterial airway epithelial invasion Source: Eur Respir J 2008; 32: 1283-1288 Year: 2008 Anti-inflammatory effects of salmeterol/fluticasone propionate (SFC) on airway T-lymphocyte populations in COPD Source: Eur Respir J 2005; 26: Suppl. 49, 203s Year: 2005 T regulatory cells: Immunomodulation by budesonide and formoterol on COPD patients Source: International Congress 2015 – Mucosal immunology: what’s new in 2015 Year: 2015 Pharmacological activities of roflumilast N-oxide, dexamethasone and formoterol in human neutrophils from healthy non-smokers and COPD patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Response to fluticasone propionate in controlling airway inflammation in steroid-naïve asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 317s Year: 2006